Arbeitspapier

The effects of off-label drug use on disability and medical expenditure

zu Verbundenen Objekten

Does using prescription drugs off-label increase disability and medical expenditure? This paper uses a unique dataset to evaluate off-label vs. on-label drug use in the US non-institutionalized population. Patients using drugs off-label have on average $515 higher medical expenditure and work-loss cost. Pharmaceutical innovation has direct and indirect effects on off-label drug use. Market size is indicative of the fraction of treatments used off-label. Our findings have implications for regulation and welfare. We address endogeneity issues by demonstrating that patients with higher disease severity do not experience higher off-label uses and by controlling for unobserved individual and condition effects.

ISBN
978-3-96973-133-8
Sprache
Englisch

Erschienen in
Series: Ruhr Economic Papers ; No. 969

Klassifikation
Wirtschaft
Analysis of Health Care Markets
Health Behavior
Technological Change: Choices and Consequences; Diffusion Processes
Thema
Productivity analyses
health care
endogenous growth theory
human capital
Arzneimittel
Gesundheitskosten
Krankheit
USA

Ereignis
Geistige Schöpfung
(wer)
Blankart, Katharina
Lichtenberg, Frank R.
Ereignis
Veröffentlichung
(wer)
RWI - Leibniz-Institut für Wirtschaftsforschung
(wo)
Essen
(wann)
2022

DOI
doi:10.4419/96973133
Handle
Letzte Aktualisierung
10.03.2025, 11:44 MEZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften - Leibniz-Informationszentrum Wirtschaft. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Objekttyp

  • Arbeitspapier

Beteiligte

  • Blankart, Katharina
  • Lichtenberg, Frank R.
  • RWI - Leibniz-Institut für Wirtschaftsforschung

Entstanden

  • 2022

Ähnliche Objekte (12)

The Effects of Off-Label Drug Use on Disability and Medical Expenditure

The Effects of Off-Label Drug Use on Disability and Medical Expenditure

Off-label drugs vs. the merits of centralised regulatory control

Artikel

Off-label drugs vs. the merits of centralised regulatory control

Dealing with Excessive Off-label Drug Use: Liability vs. Patent Prolongation

Arbeitspapier

Dealing with Excessive Off-label Drug Use: Liability vs. Patent Prolongation

Dealing with Excessive Off-label Drug Use: Liability vs. Patent Prolongation

Dealing with Excessive Off-label Drug Use: Liability vs. Patent Prolongation

A pharmacoepidemiological analysis of off-label use of marketed drugs and serious adverse drug reactions

Hochschulschrift

A pharmacoepidemiological analysis of off-label use of marketed drugs and serious adverse drug reactions

Off-label prescription of psychiatric drugs by non-psychiatrist physicians in three general hospitals in Germany

Off-label prescription of psychiatric drugs by non-psychiatrist physicians in three general hospitals in Germany

Label Free Spectromicroscopy on Drug and Drug Loaded Nanocarriers in Skin

Label Free Spectromicroscopy on Drug and Drug Loaded Nanocarriers in Skin

Off-Label-Use von Medikamenten in der Pädiatrie

Off-Label-Use von Medikamenten in der Pädiatrie

The Off-Label Use of Consumer Credit Ratings

Journal article | Zeitschriftenartikel

The Off-Label Use of Consumer Credit Ratings

Off-Label-Use von Arzneimitteln in der Palliativmedizin

Hochschulschrift

Off-Label-Use von Arzneimitteln in der Palliativmedizin

Off-Label-Use von Arzneimitteln in der Palliativmedizin

Hochschulschrift

Off-Label-Use von Arzneimitteln in der Palliativmedizin

Zum Umgang mit Off-Label-Use in der Palliativmedizin

Zum Umgang mit Off-Label-Use in der Palliativmedizin

Verbundene Objekte